Clinical Report: Correction on Prognostic Significance in Multiple Myeloma

Overview

This report addresses a correction in the ethics approval number for a study investigating the prognostic significance of integrated evaluation of bone marrow plasma cell characteristics, Vitamin D levels, and interleukin-6 in multiple myeloma. The corrected approval number is now accurately reflected in the updated article.

Background

Understanding the prognostic factors in multiple myeloma is crucial for risk stratification and treatment planning. Recent studies have emphasized the importance of various biological markers, including bone marrow plasma cell characteristics, Vitamin D levels, and interleukin-6, in predicting patient outcomes. Accurate reporting of study details, such as ethics approval, is essential for maintaining the integrity of clinical research.

Data Highlights

No numerical or trial data is presented in the correction notice.

Key Findings

• The ethics approval number for the study was corrected from CY2025-506-01 to CY2025-344-01.
• The correction pertains to the approval from the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University.
• Written informed consent was obtained from all participants, as stated in the corrected text.
• The original article has been updated to reflect these corrections.

Clinical Implications

Clinicians should ensure that they reference the most current and accurate information when considering prognostic factors in multiple myeloma. The correction highlights the importance of ethical oversight in clinical research.

Conclusion

The correction of the ethics approval number is a critical update for the integrity of the study on prognostic factors in multiple myeloma. Accurate documentation is vital for ongoing research and clinical application.

Related Resources & Content

1. Huang, P., Zhang, F., Lin, Y., Peng, J., and Yang, Z., Front. Med, 2025 -- Investigating the Prognostic Significance of Integrated Evaluation of Bone Marrow Plasma Cell Characteristics, Vitamin D Levels, and Interleukin-6 in Multiple Myeloma
2. Blood Cancer Journal — Increased Non-Clonal Plasma Cell Proportion at Diagnosis Correlates with Better Prognosis in Multiple Myeloma
3. Blood Cancer Journal — Prognostic Significance and Consequences of Mass Spectrometry in Newly Diagnosed Multiple Myeloma Patients
4. Blood Cancer Journal — The Role of the Absolute Lymphocyte to Monocyte Ratio as a Prognostic Immune Indicator in Newly Diagnosed Multiple Myeloma
5. Blood Cancer Journal — Characterizing the Bone Marrow Plasma Proteome in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
6. EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma | Nature Reviews Clinical Oncology
7. Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders
8. 944213 | Stanford Health Care
9. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
10. Frontiers | Exploring the prognostic value of combined assessment of bone marrow plasma cell morphology, Vitamin D, and interleukin-6 in multiple myeloma
11. The role of cytokines in immune cell-mediated multiple myeloma and the identification of therapeutic targets - ScienceDirect
12. Impact of pretransplant vitamin D deficiency on immune recovery and clinical outcomes in multiple myeloma patients undergoing autologous stem cell transplantation - PubMed